Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs

Int J Mol Sci. 2022 Nov 22;23(23):14511. doi: 10.3390/ijms232314511.

Abstract

Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review.

Keywords: photoactivatable platinum prodrugs; photocatalysis; photocontrolled chemotherapeutics; photodynamic therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Ligands
  • Prodrugs* / chemistry

Substances

  • Prodrugs
  • Antineoplastic Agents
  • Ligands